Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359241240657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 21.03.2024. Verfasst von Su-Jin Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: national research foundation of korea, ministry of science and ict, south korea, JBL.
Abstract (Originalsprache)
Background
Identifying actionable driver mutations via tissue-based comprehensive genomic profiling (CGP) is paramount in treatment decisions for metastatic non-squamous, non-small-cell lung cancer (NSCLC). However, the role of CGP remains elusive in resectable NSCLC. Here, we elucidate the feasibility of CGP in early-stage NSCLC Korean patients and compare the tumor mutational burden (TMB) and mutation landscape using three different platforms.
Methods
All surgically resected NSCLC samples ( N = 96) were analyzed to assess the concordance in TMB calculation and targetable mutations using whole-exome sequencing (WES) and TruSight Oncology 500 (TSO500). In all, 26 samples were analyzed with Foundation One CDx Assay (F1CDx). Programmed death-ligand 1 (PD-L1) expression was evaluated using Vectra Polaris.
Results
Stage distribution post-surgery was 80% I ( N = 77) and 20% II ( N = 19). Ninety-nine percent ( N = 95) were adenocarcinoma. The median TMB with WES and TSO500 was 1.6 and 4.7 mut/Mb, respectively ( p < 0.05). Using all three platforms, the median TMB was 1.9, 5.5, and 4 mut/Mb for WES, TSO500, and F1CDx, respectively ( p = 0.0048). Linear regression analysis of TMB values calculated between WES and TSO500 resulted in a concordance correlation coefficient of 0.83. For the PD-L1 tumor proportion score of
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, South Korea.
ORCID-Profile: Jii Bum Lee, Byoung Chul Cho, Sun Min Lim
Förderung
- national research foundation of korea
- ministry of science and ict, south korea
- JBL
- SML
Zitieren
APA
Choi, S. J., Lee, J. B., Kim, J. H., Hong, M. H., Cho, B. C., & Lim, S. M. (2024). Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241240657
Vancouver
Choi SJ, Lee JB, Kim JH, Hong MH, Cho BC, Lim SM. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241240657
BibTeX
@article{Choi2024,
author = {Choi, Su-Jin and Lee, Jii Bum and Kim, Jae Hwan and Hong, Min Hee and Cho, Byoung Chul and Lim, Sun Min},
title = {Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359241240657}
}
EUVIMED